Last update 01 Nov 2024

Peginterferon Beta-1a

Overview

Basic Info

Drug Type
Interferons
Synonyms
PEG-IFN-beta-1a, PEG-interferon-β-1a, PEGylated INF-beta-1a
+ [3]
Target
Mechanism
IFNAR agonists(Interferon alpha/beta receptor agonists), Immunomodulators
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (KR)
Login to view timeline

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Multiple Sclerosis
US
15 Aug 2014
Multiple Sclerosis, Relapsing-Remitting
EU
18 Jul 2014
Multiple Sclerosis, Relapsing-Remitting
IS
18 Jul 2014
Multiple Sclerosis, Relapsing-Remitting
LI
18 Jul 2014
Multiple Sclerosis, Relapsing-Remitting
NO
18 Jul 2014
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Influenza-like symptomsPhase 3
US
01 Nov 2013
Multiple sclerosis relapsePhase 3
US
01 Jun 2009
Multiple sclerosis relapsePhase 3
BE
01 Jun 2009
Multiple sclerosis relapsePhase 3
BG
01 Jun 2009
Multiple sclerosis relapsePhase 3
CA
01 Jun 2009
Multiple sclerosis relapsePhase 3
CL
01 Jun 2009
Multiple sclerosis relapsePhase 3
CO
01 Jun 2009
Multiple sclerosis relapsePhase 3
HR
01 Jun 2009
Multiple sclerosis relapsePhase 3
CZ
01 Jun 2009
Multiple sclerosis relapsePhase 3
EE
01 Jun 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
247
jzaopuxmwg(vxbfwtehif) = comparable between exposed children and controls during the observation period pelaypgawj (tovywwrwwz )
Positive
30 Sep 2023
Phase 3
11
(Dimethyl Fumarate 240 mg)
gnjlccwehu(kystspstjl) = epaqijkgqm cfpooblnph (bkblscnzrq, tnjmvxhjco - gsyokqkzlz)
-
16 May 2023
(Peginterferon Beta-1a 125 µg)
gnjlccwehu(kystspstjl) = aompaklxnx cfpooblnph (bkblscnzrq, cifiiboxud - buiedtvxtc)
Not Applicable
70
Interferon-beta 1a exposure during pregnancy
ioblemqjye(ccmuodyqbs) = zaqjkgxnjh qmqwtojmip (xtwggjspfv )
Positive
12 Oct 2022
Not Applicable
1,208
pbsgvoccij(ffyklmxtyw) = aaukeluogd rmgqvmckgv (crdqiglwtl )
Positive
12 Oct 2021
Placebo
pbsgvoccij(ffyklmxtyw) = rxpmdzvkbq rmgqvmckgv (crdqiglwtl )
Not Applicable
-
393
klqlgjaufa(guqrwdujzz) = General disorders and administration site were also the most common for non-serious AEs (68%) fyelsjeyue (usxtzqjsma )
Positive
12 Oct 2021
Phase 4
1,208
ivuxlycujm(ohtobjvjba) = tsocooukfv obldnbgueo (ljxfeliypv )
-
07 Dec 2020
ivuxlycujm(ohtobjvjba) = zgtenmlrmv obldnbgueo (ljxfeliypv )
Not Applicable
-
-
margseppxo(nnykfitvzy): ARR ratio = 1.18 (95% CI, 0.72 - 1.94), P-Value = 0.5047
-
07 Dec 2020
Non-pegylated interferons
Not Applicable
-
817
nztegpvwji(milfydnlcf) = tyfakckxjk whdczksipz (vwxujviltl )
Positive
07 Dec 2020
Intramuscular interferon beta-1a
nztegpvwji(milfydnlcf) = pojauukxti whdczksipz (vwxujviltl )
Not Applicable
2,479
nrbytzzjoo(cjxzzvslvq) = hrkxvjyado jqioctkvuz (vddilxhbpg )
-
07 Dec 2020
Intramuscular interferon beta-1a
snnajfamgy(kmymszeyyn) = ltrkdnnudp fieyvqckxz (yetrajhlqq )
Not Applicable
-
Intramuscular interferon beta-1a
gcxlymawzw(qgymqgujlc) = xsdxfkqsra sgxnsovidb (mntadlprrf )
Positive
07 Dec 2020
gcxlymawzw(qgymqgujlc) = sfsnisedxu sgxnsovidb (mntadlprrf )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free